Juan C. Jaen - Dec 18, 2023 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Dec 18, 2023
Transactions value $
-$221,936
Form type
4
Date filed
12/20/2023, 04:09 PM
Previous filing
Jun 16, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Disposed to Issuer -$109K -6.13K -1.95% $17.74 308K Dec 18, 2023 Direct F1, F2
transaction RCUS Common Stock Disposed to Issuer -$113K -6.26K -2.03% $18.09 301K Dec 19, 2023 Direct F1, F3
holding RCUS Common Stock 1.22M Dec 18, 2023 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.